Product logins

Find logins to all Clarivate products below.


Glomerulonephritis – Current Treatment – Current Treatment: Physician Insights – Glomerulonephritis (US)

Glomerulonephritis (GN) is a condition involving inflammation of the glomerulus, which plays an important role in the filtration of blood into the kidney. If the glomerulus becomes inflamed and damaged, there can be a decline in kidney function, leading to chronic kidney disease (CKD). While mild GN cases may not require drug intervention, severe cases are managed with therapies like corticosteroids and immunosuppressants. This content delves deep into the dynamics of the GN therapy market, examining the management of GN patients from the perspective of nephrologists. We focus on how GN disorders, such as immunoglobulin A (IgA) nephropathy, focal segmental glomerulosclerosis (FSGS), lupus nephritis (LN), and membranous nephropathy (MN), are being treated in the United States today and the factors behind those treatment decisions.

Questions answered

  • What are U.S. specialists’ attitudes and perceptions regarding the diagnosis and management of patients with IgAN, FSGS, LN, or MN?
  • What percentage of GN patients are prescribed pharmacotherapy?
  • What are the key drug classes that nephrologists use to manage patients with GN?
  • How does treatment differ for patients with IgAN, FSGS, LN, or MN?
  • How do nephrologists adjust pharmacotherapy in response to disease progression?

Content highlights

  • Geography: United States
  • Primary research: survey of 102 U.S. nephrologists
  • Key drugs covered: RAAS inhibitors, corticosteroids, immunosuppressants
  • Key insights provided:
    • Factors influencing disease management and treatment decisions
    • Drivers and constraints of treatment selection
    • Physician-reported treatment practices and brand-level patient shares
    • Rationale for changes in treatment approach
    • Physician insight on persistency and compliance
    • Physician-reported recent / anticipated changes in brand usage or treatment approach

Product description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Related Market Assessment Reports

Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via bronchodilation…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent…
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Beta Thalassemia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. BT minor is caused by a mutation in one hemoglobin beta (HBB) gene, and transfusion-dependent…
Report
Bipolar Disorder – Current Treatment – Current Treatment: Physician Insights – Bipolar Disorder (EU5)
Bipolar disorder (BD) is a spectrum disorder characterized by recurrent episodes of aberrant mood; patients may exhibit manic, depressive, or mixed symptoms between periods of stable mood. Lithium…